Related Experiment Video
Updated: Sep 26, 2026

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis
Published on: February 10, 2026
[The future expected therapeutic approaches for ITP patients]
1Department of Blood Transfusion, Osaka University Hospital.
Idiopathic thrombocytopenic purpura(ITP) is autoimmune disorder characterized by production of anti-platelet autoantibodies. The first recommended therapy is an administration of corticosteroid. For the patients refractory to steroid, splenectomy is recommended. In a portion of patients these standard therapies are not effective, therefore, effective new therapies are looked for. In this paper following new therapeutic approaches are presented; 1) eradication of Helicobacter pylori, 2) administration of thrombopoietin, 3) administration of anti-CD40L monoclonal antibodies, 4) administration of anti-CD20 monoclonal antibodies, 5) splenic irradiation. These treatment options are now tried in a small group of refractory patients except for eradication of pylori. We hope these new therapeutics will be introduced in clinical practice in near future.
Idiopathic thrombocytopenic purpura(ITP) is autoimmune disorder characterized by production of anti-platelet autoantibodies. The first recommended therapy is an administration of corticosteroid. For the patients refractory to steroid, splenectomy is recommended. In a portion of patients these standard therapies are not effective, therefore, effective new therapies are looked for. In this paper following new therapeutic approaches are presented; 1) eradication of Helicobacter pylori, 2) administration of thrombopoietin, 3) administration of anti-CD40L monoclonal antibodies, 4) administration of anti-CD20 monoclonal antibodies, 5) splenic irradiation. These treatment options are now tried in a small group of refractory patients except for eradication of pylori. We hope these new therapeutics will be introduced in clinical practice in near future.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
